# Composite Probiotics Stabilize Lipid Metabolism in Chronic Hepatitis B Patients:A Clinical Trial

> **NCT06221605** · NA · COMPLETED · sponsor: **Wecare Probiotics Co., Ltd.** · enrollment: 84 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DIETARY_SUPPLEMENT:** Probiotic

## Key facts

- **NCT ID:** NCT06221605
- **Lead sponsor:** Wecare Probiotics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-30
- **Primary completion:** 2025-03-10
- **Final completion:** 2025-04-11
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06221605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06221605, "Composite Probiotics Stabilize Lipid Metabolism in Chronic Hepatitis B Patients:A Clinical Trial". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06221605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*